Avalyn Pharma Raises $300M in Upsized IPO
Event summary
- Avalyn Pharma priced its upsized IPO at $18 per share, raising $300M from 16.7M shares.
- Underwriters have a 30-day option to purchase an additional 2.5M shares.
- Shares began trading on Nasdaq under the ticker 'AVLN' on April 30, 2026.
- Proceeds will support clinical trials for inhaled therapies targeting rare respiratory diseases.
The big picture
Avalyn's $300M IPO underscores investor appetite for innovative respiratory disease treatments, particularly those targeting pulmonary fibrosis. The company's lung-targeted approach aims to differentiate itself in a competitive space dominated by oral antifibrotics. Success hinges on clinical trial outcomes and the ability to scale manufacturing for inhaled therapies.
What we're watching
- Clinical Progress
- How the MIST and AURA Phase 2 trials for AP01 and AP02 will impact investor confidence.
- Market Reception
- Whether Avalyn can sustain momentum post-IPO amid competitive pressures in rare respiratory disease treatments.
- Execution Risk
- The pace at which Avalyn advances its inhaled fixed-dose combination therapy (AP03) toward commercialization.
Related topics